trending Market Intelligence /marketintelligence/en/news-insights/trending/RpEI5mgm-vytwtQKfJDHLQ2 content esgSubNav
In This List

Mylan launches generic version of Novartis Paget's disease drug

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Mylan launches generic version of Novartis Paget's disease drug

Mylan NV launched Zoledronic acid injection in the U.S., a generic version of Novartis AG's Reclast injection.

The company received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for the product, which is indicated for the treatment of Paget's disease of bone in men and women.

According to QuintilesIMS Health data, Zoledronic acid injection in 5 milligram/100 milliliters single-dose vial had U.S. sales of about $22.1 million for the 12 months ending March 31.